Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 701–800 of 1,733
Moyad, M. A. (2020) · Current Urology Reports · doi:10.1007/s11934-020-0967-4 · Cited by 8
Rostami, T., Mohammadifard, M. A., Ansari, S., Kiumarsi, A., Maleki, N., Kasaeian, A., Aghamahdi, F., Rad, S., & Ghavamzadeh, A. (2020) · Fertility Research and Practice · doi:10.1186/s40738-020-00071-6 · Cited by 9
Reproductive Dysfunctions in Males with Type 2 Diabetes Mellitus: An Updated Review
Ray, S., & Pramanik, S. (2020) · EMJ Diabetes · doi:10.33590/emjdiabet/20-00171 · Cited by 10
Vena, W., VACCALLUZZO, L., Vignera, S. L., Morenghi, E., d’Agostino, M. C., Perri, A., Giammusso, B., Lania, A. G., Aversa, A., & Pizzocaro, A. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03686-1 · Cited by 8
Plasma Metabonomics in Insulin-Resistant Hypogonadic Patients Induced by Testosterone Treatment
Zolla, L., Grande, G., & Milardi, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147754 · Cited by 9
“The aim of testosterone replacement therapy is to increase the serum testosterone level in the medium–normal range and the resolution of or reduction in hypogonadism symptoms [21].”
BackgroundHammoud, S., van den Bemt, B. J. F., Jaber, A., & Kurdi, M. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.03.057 · Cited by 10
Long vs Short Acting Testosterone Treatments: A Look at the Risks
Gurayah, A. A., Dullea, A. D., Weber, A., Masterson, J. M., Khodamoradi, K., Mohamed, A. I., & Ramasamy, R. (2022) · Urology · doi:10.1016/j.urology.2022.11.016 · Cited by 12
Effect of thyroxine replacement on leydig cell and sertoli cell function in men with hypothyroidism
Kamalanathan, S., Ambigapathy, J. S., Sahoo, J., Kumar, R., & Perumal, N. L. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_69_20 · Cited by 10
“3 mIU/mL).[11] Similarly, hypergonadotropic hypogonadism was diagnosed when low total testosterone was associated with elevated LH (LH >9.”
BackgroundRole of Obesity in Human Health and Disease
Rao, V., & Rao, L. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.90990 · Cited by 9
Santi, D., Spaggiari, G., Furini, C., Griseta, V., Zizzi, E. A., Granata, A. R. M., & Simoni, M. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02671-9 · Cited by 13
“Despite several scientific societies produced guidelines about correct testosterone prescription [16 , 17], this rate is seems to be continuously increasing year after year [18 , 19 ].”
Laboratory Monitoring in Transgender and Gender-Diverse Individuals
Nolan, B. J., & Cheung, A. S. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf001 · Cited by 12
Cipriani, S., Todisco, T., Ghiandai, N., Vignozzi, L., Corona, G., Maggi, M., & Rastrelli, G. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01586-5 · Cited by 8
“The Endocrine Society (ES) guidelines [7] suggest, in absence of neurological disturbances, 5.”
BackgroundInfluentialNegri, F., Pozzi, E., Corsini, C., et al. (2024) · The World Journal of Men s Health · doi:10.5534/wjmh.240184 · Cited by 8
“A tT cut-off value higher or lower than 3 ng/mL was used to define eugonadism and TD, respectively [19].”
Wang, A., Arver, S., Flanagan, J. N., Gyberg, V., Näsman, P., Ritsinger, V., & Mellbin, L. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118802543 · Cited by 9
Quantifying the variability in the assessment of reproductive hormone levels
Abbara, A., Adams, S., Phylactou, M., Izzi‐Engbeaya, C. N., Mills, E., Thurston, L., Koysombat, K., Hanassab, S., Heinis, T., Tan, T., et al. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.11.010 · Cited by 10
Zitzmann, M., Cremers, J., Krallmann, C., Soave, A., & Kliesch, S. (2024) · Andrology · doi:10.1111/andr.13626 · Cited by 12
Why Do We Need New Markers for Male Hypogonadism and How Seminal Proteomics Might Solve the Problem?
Grande, G., Milardi, D., Baroni, S., Urbani, A., & Pontecorvi, A. (2020) · Protein and Peptide Letters · doi:10.2174/0929866527666200505214021 · Cited by 9
Drugs and androgenetic alopecia: What to look out for
Perez, S. M., Williams, K. N., Nguyen, B., & Tosti, A. (2024) · JAAD reviews. · doi:10.1016/j.jdrv.2024.09.004 · Cited by 11
Macdowall, W. G., Clifton, S., Palmer, M. J., Tanton, C., Copas, A. J., Lee, D. M., Mitchell, K. R., Mercer, C. H., Sonnenberg, P., Johnson, A. M., et al. (2021) · The Journal of Sex Research · doi:10.1080/00224499.2021.1968327 · Cited by 11
Lykhonosov, M. P., Babenko, A. Y., Макарьин, В. А., & Fedotov, Y. N. (2020) · Problems of Endocrinology · doi:10.14341/probl12223 · Cited by 8
“Применяемые в заместительной терапии тестостероном дозы андрогена и его производных, показания и противопоказания, схемы назначения, длительность, кратность медицинских осмотров и объем лабораторных и инструментальных обследований подробно регламентируются клиническими рекомендациями (протоколами) или национальными ру…”
InfluentialLima, G. H. O., Kolliari-Turner, A., Wang, G., Ho, P., Meehan, L. R., Roeszler, K. N., Seto, J. T., Malinsky, F. R., Karanikolou, A., Eichhorn, G., et al. (2022) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000001037 · Cited by 8
“100 mg/wk based on clinical recommendations of testosterone replacement therapy.(30,31) Self-reported AAS cycles, other performance-enhancing Drugs (PEDs), and PCT protocols are presented in Supplemental Digital Content 1 (see Table 1, http://links.”
BackgroundTestosterontherapie im Alter bei Hypogonadismus und Komorbiditäten
Zitzmann, M. (2020) · Der Internist · doi:10.1007/s00108-020-00796-y · Cited by 9
Corona, G., Rastrelli, G., Dicuio, M., Concetti, S., Minnetti, M., Pivonello, R., Isidori, A. M., Sforza, A., & Maggi, M. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03208-3 · Cited by 11
Heald, A. H., Stedman, M., Whyte, M., Livingston, M. A., Albanese, M., Ramachandran, S., & Hackett, G. I. (2021) · Clinical Endocrinology · doi:10.1111/cen.14412 · Cited by 8
Samango‐Sprouse, C. A., Yu, C., Porter, G. F., Tipton, E. S., Lasutschinkow, P. C., & Gropman, A. L. (2020) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000612 · Cited by 7
“The Endocrine Society published updated guidelines in 2018 on testosterone therapy in hypogonadal men but did not adjust recommendations regarding testosterone therapy for men with 47,XXY specifically [39].”
MethodUso da testosterona no envelhecimento masculino
Calixto, I. T., & Prazeres, T. C. M. M. (2019) · Revista de Investigação Biomédica · doi:10.24863/rib.v10i3.315 · Cited by 11
Nascimento, H. S., Corrêa, M. G., Lemos, O. L., Lima, H. N., & Amaral, L. S. D. B. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.106938 · Cited by 12
Testosterone Therapy: Increase in Hematocrit is Associated with Decreased Mortality
Strange, R. C., König, C. S., Ahmed, A., Hackett, G. I., Haider, A., Haider, K. S., Desnerck, P., Saad, F., Lorde, N., Maarouf, A., et al. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0019 · Cited by 9
Donald, D. M., McDonnell, T., O’Reilly, M., & Sherlock, M. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09897-7 · Cited by 8
“Diagnosis requires two separate early morning, fasting samples, demonstrating low testosterone levels with either low or inappropriately normal gonadotrophins [22].”
BackgroundInfluentialDigit ratio (2D:4D) and testosterone supplementation
Manning, J. T., Cook, C. J., & Crewther, B. T. (2019) · Early Human Development · doi:10.1016/j.earlhumdev.2019.104843 · Cited by 7
Adult Male Hypogonadism: A Review
Anawalt, B. D., O’Connor, K., & Grossmann, M. (2026) · JAMA · doi:10.1001/jama.2026.8526 · Cited by 12
Derwand, D., Zierau, O., Thieme, D., & Keiler, A. M. (2023) · Andrology · doi:10.1111/andr.13466 · Cited by 8
Arora, S., Moclair, B., Murphy, K., Jaffe, J., & Kaminetsky, J. (2018) · Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.09.017 · Cited by 6
“Transdermal disadvantages include transference, that is, T possibly transferred to others via skin-to-skin contact and the application of 2 patches daily due to serum T levels in the lownormal range in some androgen-deficient men.(2,11) Transbuccal disadvantages include gum-related adverse events (AEs) in 16% of treat…”
BackgroundAn Individualized Approach to Managing Testosterone Therapy in the Primary Care Setting
Dobs, A. S., & Campbell, K. J. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s364189 · Cited by 8
“Because testosterone concentrations exhibit significant diurnal and day-to-day variations, clinical practice guidelines generally recommend 2 separate morning measurements of serum total testosterone while fasting and in the absence of acute illness to diagnose testosterone deficiency.(1,13,14,17,18) According to the…”
BackgroundMethodInfluentialThe anabolic applications of androgens in older adults with functional limitations
Gattu, A. K., Goldman, A. L., Guzelce, E. C., Galbiati, F., & Bhasin, S. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09766-1 · Cited by 9
Self-citationObesity and sexual desire: a systematic review and meta-analysis
Biernikiewicz, M., Rusiecka, A., & Kałka, D. (2025) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdaf057 · Cited by 7
Kang, B. J., Noh, M., & Park, H. J. (2021) · The World Journal of Men s Health · doi:10.5534/wjmh.200174 · Cited by 8
“Testosterone and sexual function are the most closely related, but it is well known that body composition, cognitive function, mood change, and physical function are also related to testosterone [1-3,11,15].”
BackgroundJasuja, R., Pencina, K. M., Lawney, B. P., Stephens‐Shields, A. J., Ellenberg, S. S., Snyder, P. J., & Bhasin, S. (2024) · Andrology · doi:10.1111/andr.13707 · Cited by 9
Self-citationPiatkowski, T. M., Ayurzana, L., King, M. A., Hattingh, L., & McMillan, S. S. (2025) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-025-00636-y · Cited by 11
“The diagnostic process involves clinical assessments, hormonal assays, and a reproductive hormone profile to determine the need for lifelong testosterone replacement [13].”
Chang, S., Larsen, O. H., Hvas, A., Skakkebaek, A. H., Gravholt, C. H., & Münster, A. B. (2022) · Andrology · doi:10.1111/andr.13330 · Cited by 8
Kwon, H., Roh, E., Ahn, C. H., Kim, H. K., Ku, C. R., Jung, K. Y., Lee, J. H., Kim, E. H., Suh, S., Hong, S., et al. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1627 · Cited by 8
“Because testosterone levels exhibit a diurnal variation with peak values in the early morning, testosterone concentration should be measured in the morning after an overnight fast [35].”
BackgroundInfluentialFree testosterone and cardiometabolic parameters in men: comparison of algorithms
Holmboe, S. A., Jasuja, R., Lawney, B. P., Priskorn, L., Joergensen, N., Linneberg, A. R., Jensen, T. K., Skakkebæk, N. E., Juul, A., & Andersson, A. (2021) · Endocrine Connections · doi:10.1530/ec-20-0552 · Cited by 8
“One of the most commonly used indirect algorithms, which have been acknowledged by the Endocrine Society because of its clinical relevance in relation to hypogonadism, was suggested by Vermeulen et al. (1, 11, 12).”
MethodDalmiglio, C., Bombardieri, A., Mattii, E., Sestini, F., Fioravanti, C., Castagna, M. G., Fiorini, M., Dotta, F., & Cantara, S. (2024) · HORMONES · doi:10.1007/s42000-023-00522-x · Cited by 8
Devine, K., Russell, C. D., Blanco, G. R., Walker, B. R., Homer, N. Z. M., Denham, S. G., Simpson, J., Leavy, O. C., Elneima, O., McAuley, H., et al. (2024) · Clinical Endocrinology · doi:10.1111/cen.15012 · Cited by 7
“15 There was a clear inverse correlation with disease severity, with an 80% drop in total testosterone between the least and most severely affected groups (6.9 vs. 1.2 nmol/L).”
Influentialvan Os, J., Smit, D. L., Bond, P., & de Ronde, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1621558 · Cited by 7
“Medically prescribed testosterone replacement therapy (TRT) typically involves weekly doses of 75 to 100 mg of testosterone (56).”
Herati, A. S., Kohn, T. P., & Kassiri, B. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2019.12.39 · Cited by 7
“Hypogonadism is defined by the Endocrine Society as a testosterone level <300 ng/dL and is accompanied by associated symptoms, such as low energy and impaired libido (1).”
BackgroundCilio, S., Pozzi, E., Fallara, G., Belladelli, F., Raffo, M., Lanzaro, F., Bertini, A., Boeri, L., Capogrosso, P., d'Arma, A., et al. (2023) · Andrology · doi:10.1111/andr.13506 · Cited by 8
Varanoske, A. N., Harris, M. N., Hebert, C., Howard, E. E., Johannsen, N. M., Heymsfield, S. B., Greenway, F. L., Margolis, L. M., Lieberman, H. R., Church, D. D., et al. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100819 · Cited by 9
Leśniak, K., Rymarz, A., Sobol, M., et al. (2022) · Nutrients · doi:10.3390/nu14214461 · Cited by 7
“The value of the assessment of free or bioavailable testosterone levels has not yet been established, perhaps due to the fact that such measurements could be either difficult or unreliable, and currently they are not routinely or commercially available [45,46].”
BackgroundUnveiling the shared genetic architecture between testosterone and polycystic ovary syndrome
Sun, S., Liu, Y., Li, L., Xiong, L., Jiao, M., Yang, J. Z., Li, X., & Liu, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-75816-0 · Cited by 9
“Factors influencing SHBG production include age, estrogen, thyroid hormones, liver disease, obesity, insulin resistance, and androgens 17,18 .”
BackgroundSchumacher, K. A., & Gosmanov, A. R. (2022) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096221111774 · Cited by 8
Scala, A., Gender Incongruence Interdisciplinary Group, Graziani, A., Vianello, F., Ferlin, A., & Garolla, A. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.24.04171-x · Cited by 8
Hsu, P.-S., Hung, C.-L., Tu, S.-K., Chen, H.-H., Yang, D., & Liao, C. (2021) · Journal of Diabetes Research · doi:10.1155/2021/1347588 · Cited by 9
“Testosterone (T) plays an important role in the maintenance and development of male reproductive and sexual functions, muscle and bone health, body composition, and cognitive functions [1].”
BackgroundFeuz, M. B., Nelson, D., Miller, L. B., Zwerdling, A. E., Meyer, R. G., & Meyer‐Ficca, M. L. (2024) · Reproduction · doi:10.1530/rep-23-0486 · Cited by 8
Sex hormones, obesity and type 2 diabetes-is there a link?
Gambineri, A. (2018) · Endocrine Abstracts · doi:10.1530/endoabs.56.s18.1 · Cited by 7
Nowak, E., Vogel, F., Braun, L., Zopp, S., Rubinstein, G., Schilbach, K., Bidlingmaier, M., Zimmermann, P., Thorsteinsdottir, J., Schweizer, J. R. D. O. L., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae097 · Cited by 10
Milionis, C., Ilias, Ι., Venaki, E., & Koukkou, E. G. (2022) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200087 · Cited by 11
“In men with hypogonadism, it has been shown to enhance libido and overall sexual function, increase bone mineral density and skeletal muscle mass, and decrease body fat [14].”
Sex-Specific Associations of Testosterone and Genetic Factors With Health Span
Zhao, X., Liang, S., Wang, N., Hong, T., Sambou, M. L., Fan, J., Zhu, M., Wang, C., Hang, D., Jiang, Y., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.773464 · Cited by 8
Mok, S. F., Fennell, C., Savkovic, S., Turner, L., Jayadev, V., Conway, A. J., & Handelsman, D. J. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz195 · Cited by 9
An extracellular vesicle-mediated mitochondrial transfer network critical for testosterone synthesis
Xia, K., Zhang, S., Peng, H., Chen, H. J., Yang, C., Yu, J., Luo, P., Lu, Q., Chen, H., Huang, L., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01896-x · Cited by 12
“Beyond the reproductive effects, testosterone exerts important regulatory effects on systemic physiology, including muscle formation, bone mineralization, fat metabolism and cognitive processes 1,4–6 .”
Babcock, M. C., DuBose, L. E., Hildreth, K. L., Stauffer, B. L., Kohrt, W. M., Wenner, M. M., & Moreau, K. L. (2025) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00218.2024 · Cited by 12
“It is important to note that low serum testosterone alone does not meet the definition of “androgen deficiency,” which includes signs and symptoms such as reduced libido, erectile dysfunction, depressed mood, poor concentrations and memory, and/or increased fatigue (33).”
Ory, J., Diaz, P., Rivero, M., Clavijo, R. I., Thirumavalavan, N., Blachman-Braun, R., Loloi, J., Bernstein, A., & Ramasamy, R. (2022) · European Urology Focus · doi:10.1016/j.euf.2022.09.001 · Cited by 6
Sansone, A., Kliesch, S., Dugas, M., Sandhowe‐Klaverkamp, R., Isidori, A. M., Schlatt, S., & Zitzmann, M. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01561-0 · Cited by 8
Majumdar, S., Mukherjee, J. J., Ray, S., Goswami, S., Jude, E. B., Biswas, A. K., Hanumanthu, A., John, M., Sinha, B., Ghosal, S., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102191 · Cited by 10
Low testosterone and cardiometabolic risks in a real-world study of US male firefighters
Ranadive, S. M., Lofrano‐Porto, A., Soares, E. D. M. K. V. K., Eagan, L. E., Porto, L. G. G., & Smith, D. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-93603-z · Cited by 7
A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product
Bernstein, J. S., & Dhingra, O. P. (2024) · Therapeutic Advances in Urology · doi:10.1177/17562872241241864 · Cited by 7
Liang, J., Peng, T., Hu, J., So, K., Zhang, H., Chen, G., & Zhang, Y. (2025) · Biomolecules · doi:10.3390/biom15030425 · Cited by 7
Elenkov, A., Al-Jebari, Y., Giwercman, Y. L., & Giwercman, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0734 · Cited by 7
Andropause symptoms and sickness absence in Japanese male workers: a prospective study
Hirokawa, K., Fujii, Y., Taniguchi, T., Takaki, J., & Tsutsumi, A. (2020) · The Aging Male · doi:10.1080/13685538.2020.1862078 · Cited by 13
“This finding is consistent with several previous studies that found that the biochemical demonstration of testosterone deficiency is not sufficient to define the clinical condition of LOH, and the presence of specific symptoms is an essential requirement [33,34].”
ResultWalker, W. C., Werner, J. K., Agyemang, A. A., Allen, C. M., Resch, J. E., Troyanskaya, M., & Kenney, K. (2022) · Brain Injury · doi:10.1080/02699052.2022.2068185 · Cited by 6
Potter, N. J., Tomkinson, G. R., Dufner, T. J., Walch, T. J., Roemmich, J. N., Wilson, P. B., & Fitzgerald, J. S. (2021) · The Journal of Strength and Conditioning Research · doi:10.1519/jsc.0000000000004146 · Cited by 9
“, decreased fat mass and increased fat-free mass), muscle strength, and bone mineral density and strength (5).”
BackgroundInfluentialCilio, S., Boeri, L., Pozzi, E., Fallara, G., Belladelli, F., Corsini, C., Capogrosso, P., d’Arma, A., Imbimbo, C., Palmieri, A., et al. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-022-00647-4 · Cited by 6
“Hypogonadism was de fi ned as tT ≤ 3ng/ml [30].”
McGuirt, A. F., & Brezing, C. (2024) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2292012 · Cited by 6
Panizzon, M. S., Bree, K. K., Hsieh, T., Hauger, R. L., Xian, H., Jacobson, K. C., Lyons, M. J., & Franz, C. E. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.08.016 · Cited by 8
“The possible symptom presentation of testosterone deficiency is extensive, ranging from decreased libido to reductions in muscle mass and strength [8].”
BackgroundDiagnosis and Management of Neuroendocrine Disorders of Survivors of Brain Tumors
Erickson, D. Z., & Donegan, D. M. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321059 · Cited by 6
Judge, C., Lightowler, D., Singh, A., Yeap, B. B., & Thin, L. W. Y. (2024) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izae177 · Cited by 5
Diurnal Variation of Serum Total Testosterone in Women: A Single-Center Study From Basrah
Algburi, H. D., Hamza, A., & Mansour, A. A. (2023) · Cureus · doi:10.7759/cureus.47677 · Cited by 9
“This approach was chosen due to the lack of clear data regarding testosterone measurement in women while fasting, in contrast to the well-established guidelines for men [16].”
ResultFazekas, C., Linder, D., Matzer, F., Vajda, C., Avian, A., Theiler‐Schwetz, V., Trummer, C., Došen, J., Rokvic, J., Mohl, M., et al. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01809-y · Cited by 8
Agretti, P., Pelosini, C., Bianchi, L., Grosso, A. D., Saba, A., Canale, D., & Sessa, M. R. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01304-7 · Cited by 6
Moyad, M. A. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2021.12.006 · Cited by 6
Biochemical Hypogonadism in Aging Testicular Cancer Survivors: A Clinical Challenge
Fosså, S. D., Bjerner, L. J., Tandstad, T., Brydøy, M., Dahl, A. A., Nome, R. V., Negaard, H. F. S., Myklebust, T. Å., & Haugnes, H. S. (2025) · European Urology Open Science · doi:10.1016/j.euros.2024.12.010 · Cited by 6
Cannarella, R., Calogero, A. E., Condorelli, R. A., Aversa, A., & Vignera, S. L. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820966438 · Cited by 6
An oral lipidic native testosterone formulation that is absorbed independent of food
Newell-Price, J. D. C., Huatan, H., Quirke, J., Porter, J. B., Daniel, E., Mumdzic, E., Voet, B., Keevil, B. G., Whitaker, M. J., & Ross, R. J. M. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0606 · Cited by 6
Microsurgical varicocelectomy: novel applications to optimize patient outcomes
Lipshultz, L. I., Ramasamy, R., Sandlow, J. I., Hotaling, J. M., Eisenberg, M. L., Niederberger, C., & Brannigan, R. E. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.08.057 · Cited by 6
Body Composition by DXA in Patients with Klinefelter and Kallmann Syndrome: The Kama Study
Buoso, C., Delbarba, A., Riva, M., Artifoni, G., Gatta, E., Farina, D., Quirós-Roldán, E., Ferlin, A., & Cappelli, C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf565 · Cited by 6
Hart, N. H., & Newton, R. U. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.015 · Cited by 6
“In alignment with clinical treatment of men with chronically low testosterone levels, the updated Endocrine Society clinical practice guidelines recommend a wide array of pharmacotherapies, the most prominent of which is testosterone enanthate; an easily administered synthetic derivative of testosterone through intram…”
BackgroundTestosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial
Bhasin, S., Burnett, A. L. “., Gagliano‐Jucá, T., Storer, T. W., Reid, K. F., Shang, Y. V., Privat, F., Chandra, M. S., Weiss, M., Beleva, Y. M., et al. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.1343 · Cited by 9
Self-citationDelbarba, A., Cosentini, D., Facondo, P., Laganà, M., Pezzaioli, L. C., Cremaschi, V., Alberti, A., Grisanti, S., Cappelli, C., Ferlin, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1128061 · Cited by 7
Effects of testosterone dose on depression-like behavior among castrated adult male rats
Ren, Z., Xiao, L., Xie, Y., Huang, Z., Lin, S., Si, L., & Wang, G. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107046 · Cited by 6
Kabha, M., Hadar, D., Kassem, S., Dekel, Y., Cohen, H., & Zaina, A. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70064 · Cited by 7
“Furthermore, TRT should be discontinued if haemato-crit exceeds 54% or if haemoglobin rises above 18.5 g/dL in men due to the potential increased risk of thromboembolic events [8, 11, 12].”
InfluentialWalravens, J., Snaterse, G., Narinx, N., Reyns, T., Uytfanghe, K. V., Vanderschueren, D., Wu, F. C. W., Kaufman, J., Antonio, L., Fiers, T., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf507 · Cited by 6
Self-citationNeidhart, A., von Wyl, V., Käslin, B., Henzen, C., & Fischli, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1496906 · Cited by 7
Reproductive and Nonreproductive Actions of Testosterone
Bhasin, S., & Jasuja, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65412-0 · Cited by 10
Self-citationSchwarzman, L. S., de Souza, R. P., Ohlander, S. J., Mima, M., Abern, M. R., Andriole, G. L., Freedland, S. J., & Moreira, D. M. (2019) · Urology · doi:10.1016/j.urology.2019.11.004 · Cited by 7
Sulu, C., Gül, N., Tanrıkulu, S., Doğanşen, S. Ç., Öztürk, F. Y., Saraç, B., Ersungur, E. B., Aydın, E. T., Şahin, S., Özkaya, H. M., et al. (2023) · Pituitary · doi:10.1007/s11102-023-01342-3 · Cited by 6
Sachdev, S., Cucchiara, A. J., & Snyder, P. J. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa141 · Cited by 6
Self-citationRudman, Y., & Shimon, I. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.11.001 · Cited by 6
Yu, Y., Wang, Y., Xu, L., Li, W., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1319582 · Cited by 6
Baldini, S., Khattak, A. S., Capogrosso, P., Antonini, G., Dehò, F., Schifano, F., & Schifano, N. (2023) · Brain Sciences · doi:10.3390/brainsci13121652 · Cited by 7
“It is an inherent limitation of spontaneous reporting, however, that firm evidence cannot usually be produced.”
BackgroundLi, Y.-R., Tsao, S., Chen, C., Hou, C., Tsui, K.-H., Juang, H., & Lin, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226808 · Cited by 6
“Studies have extensively investigated the association between obesity and type-2diabetes-mellitus-related secondary hypogonadism, also known as male obesity-associated secondary hypogonadism (MOSH).”
Background
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.